Biomus is a potent immunosuppressive agent that is effective in allograft prophylaxis after organ transplantation, for therapy of acute rejection and in treatment of different immune diseases.
Bioavailability range from 10-60%. Reaches maximum blood levels after 1-2 hours after dosing. Half-life ranges from 8-24 hours. Significantly reduces the incidence and severity of acute rejection rates in organ transplantation
Tacrolimus 0.25mg, 0.5mg, 1mg, 2mg Capsules
MODE OF ACTION:
Tacrolimus selectively inhibit calcineurin, thereby impairing the transcription of interleukin (IL)-2 and several other cytokines in T lymphocytes. Tacrolimus leads to suppression of the immune system by inhibiting the production of Interleukin-2. Our body has a type of immune response called acquired immune response which creates a memory for the body after an infection from a certain pathogen so that when the body suffers from the same infection again, it will be able to fight against the infection even more vigorously.
T-cells which are a type of lymphocytes or White Blood Cells (WBC) are actually quite necessary for the body’s acquired immune response and interleukin-2 promotes the development and proliferation of T-cells. Tacrolimus by inhibiting interleukin-2; which is a protein and a cytokine signaling molecule of the immune system, also inhibits the body’s immune response. Thus it helps the body in retaining newly transplanted organs.
- Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants.
- Treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants.
- Treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate.
In combination with azathioprine and corticosteroids.
Adults: 0.2 mg/kg/day PO in 2 divided doses given 12 hours apart in combination with azathioprine and corticosteroids. The first dose may be administered within 24 hours of transplantation but should be delayed until renal function has recovered.
In combination with mycophenolate mofetil, corticosteroids, and an IL-2 receptor antagonist.
Adults: 0.1 mg/kg/day PO in 2 divided doses given 12 hours apart in combination with mycophenolate mofetil, corticosteroids, and daclizumab or basiliximab induction therapy. The first dose may be administered within 24 hours of transplantation but should be delayed until renal function has recovered.
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.